HomeCompareCLVLY vs PLD

CLVLY vs PLD: Dividend Comparison 2026

CLVLY yields 0.36% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.60M in total portfolio value
10 years
CLVLY
CLVLY
● Live price
0.36%
Share price
$7.24
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$305.5K
Annual income
$199,327.02
Full CLVLY calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — CLVLY vs PLD

📍 PLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVLYPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVLY + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVLY pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVLY
Annual income on $10K today (after 15% tax)
$30.66/yr
After 10yr DRIP, annual income (after tax)
$169,427.97/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $3,868,688.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVLY + PLD for your $10,000?

CLVLY: 50%PLD: 50%
100% PLD50/50100% CLVLY
Portfolio after 10yr
$3.11M
Annual income
$2,475,026.10/yr
Blended yield
79.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CLVLY
No analyst data
Altman Z
17.2
Piotroski
5/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVLY buys
0
PLD buys
0
No recent congressional trades found for CLVLY or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVLYPLD
Forward yield0.36%3.10%
Annual dividend / share$0.03$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%74.4%
Portfolio after 10y$305.5K$5.91M
Annual income after 10y$199,327.02$4,750,725.19
Total dividends collected$276.6K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CLVLY vs PLD ($10,000, DRIP)

YearCLVLY PortfolioCLVLY Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$10,772$72.13$11,241$540.96$469.00PLD
2$11,671$145.24$13,019$991.13$1.3KPLD
3$12,783$294.14$15,801$1,870.97$3.0KPLD
4$14,279$602.13$20,609$3,701.21$6.3KPLD
5$16,536$1,257.27$29,919$7,867.97$13.4KPLD
6$20,415$2,721.45$50,631$18,617.74$30.2KPLD
7$28,124$6,280.07$105,528$51,352.20$77.4KPLD
8$46,264$16,171.07$287,364$174,449.42$241.1KPLD
9$99,224$49,721.74$1,081,760$774,280.77$982.5KPLD
10$305,497$199,327.02$5,908,209$4,750,725.19$5.60MPLD

CLVLY vs PLD: Complete Analysis 2026

CLVLYStock

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Full CLVLY Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CLVLY vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVLY vs SCHDCLVLY vs JEPICLVLY vs OCLVLY vs KOCLVLY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.